Difference between revisions of "Part:BBa K4182009"
| Line 7: | Line 7: | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
| − | ==Usage&Biology== | + | ===Usage&Biology=== |
| + | |||
| + | <!==Usage&Biology== | ||
===The original components are replaced with carriers to achieve more efficient expression=== | ===The original components are replaced with carriers to achieve more efficient expression=== | ||
| Line 62: | Line 64: | ||
Figure 9: Team 2020 Plasmids | Figure 9: Team 2020 Plasmids | ||
| − | + | > | |
| − | + | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
<partinfo>BBa_K4182009 SequenceAndFeatures</partinfo> | <partinfo>BBa_K4182009 SequenceAndFeatures</partinfo> | ||
Revision as of 05:45, 12 October 2022
A circuit for efficient exopolysaccharide synthesis
we selected the E.coli-pgmA+E.coli-GalU gene (later referred to as EE gene) with the best EPS expression with the LacI manipulator to form plasmid IV where the GalU gene and the pgmA gene set from E. coli were synthesized into the EE gene, In specific experiments we obtained the EE gene, LacI gene in separate isolation and extraction Figure In our specific experiments, we isolated and extracted EE gene, LacI gene pSB1K3 plasmid vector and recovered them, and then performed GoldenGate ligation by using Bsa I enzyme cleavage site. Because the plasmid copy number was not high, we were unable to obtain the linker. So we changed to high copy pSEVA341 plasmid and re-linked it to obtain new plasmid IV and successfully constructed it